LYC-55716 advancing in Phase 2a portion of ARGON monotherapy study and in Phase 1b study in combination with pembrolizumab NEW YORK and ANN ARBOR, Mich., May 30, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced presentations of the company’s novel immuno-oncology therapeutic candidate, LYC-55716, to take… Read More

NEW YORK and ANN ARBOR, Mich., May 16, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the publication of new preclinical research findings describing the potential utility of the Company’s most advanced cancer immunotherapy platform, selective RORgamma agonists, in adoptive cell therapy applications. RORgamma is a… Read More

Clinical benefit observed in multiple patients treated with single agent RORgamma Agonist NEW YORK and ANN ARBOR, Mich., April 17, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced new clinical findings from the Phase 1 portion of its Phase 1/2a ARGON study of the company’s novel… Read More

LYC-55716 Currently Advancing in Phase 2a Portion of ARGON Study and in Phase 1b Combination Trial with Pembrolizumab   NEW YORK and ANN ARBOR, Mich., April 5, 2018 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced that the Company will present new clinical and preclinical findings from… Read More

First-In-Class RORgamma Agonist Also Advancing in Phase 2a Portion of ARGON Study NEW YORK and ANN ARBOR, January 4, 2018 — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the initiation of a Phase 1b clinical trial of the company’s novel immuno-oncology therapeutic candidate, LYC-55716, in combination with pembrolizumab… Read More

Data Support the Enrollment of Multiple Solid Tumor Cohorts in Trial NEW YORK and ANN ARBOR, November 7, 2017 — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the presentation of scientific data supporting the selection of tumor types for Lycera’s ongoing Phase 1/2a ARGON study of its novel… Read More

Cohort Expansion In Select Tumors of Interest NEW YORK and ANN ARBOR, Mich., Oct. 19, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the initiation of the Phase 2a portion of the company’s Phase 1/2a ARGON study of its novel immuno-oncology therapeutic candidate, LYC-55716 is a… Read More

Preliminary Findings from Phase 1/2a Trial Demonstrate LYC-55716 Was Well-Tolerated Durable Disease Stabilization Observed in Heavily Pretreated Patients NEW YORK and ANN ARBOR, Mich., September 11, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the first presentation of clinical findings from the initial three cohorts of… Read More

NEW YORK and ANN ARBOR, Mich., Mar. 13, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that Pablo J. Cagnoni, M.D., has been elected to the Company’s Board of Directors, effective immediately. The Company also announced that Timothy M. Mayleben will step down from his position on… Read More

First-In-Class RORgamma Agonist to Begin Phase 1 – Dose Finding and Safety Assessment NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients… Read More